Medtronic Launches In.Pact Admiral Drug-Coated Balloon in Canada

 

February 9, 2017—Medtronic Canada, a subsidiary of Medtronic, announced it has obtained Health Canada license for the In.Pact Admiral drug-coated balloon (DCB), a primary endovascular device for the treatment of peripheral artery disease (PAD) in the superficial femoral arteries (SFA) and popliteal arteries.

According to the company, the In.Pact Admiral DCB is supported by evidence from more than 20 individual clinical trials demonstrating durable safety and clinical benefits. Three-year data from the IN.PACT SFA clinical trial presented in September at VIVA 2016, the Vascular Interventional Advances conference, demonstrated high rates of primary patency and low rates of clinically driven target lesion revascularization.

In Medtronic Canada's announcement, Andrew Benko, MD, commented, “Patients experiencing incapacitating intermittent claudication or rest pain need a safe and durable treatment option. In my practice, In.Pact Admiral DCB will be the device of choice for such patients with femoropopliteal lesions giving the opportunity for outstanding clinical results with very low reintervention rates. This technology has been one of the most significant advancements I have seen in the endovascular management of PAD.” Dr. Benko is from Centre Hospitalier Universitaire de Sherbrooke in Sherbrooke, Quebec.

 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.